The effect of Oliceridine and sufentanil on the quality of postoperative recovery in elective gynecologic laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090783

Enrollment

Unknown

Registered

2024-10-13

Start date

2024-10-14

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecologic laparoscopic surgery

Interventions

Oxeligidine group (Group O):Oxeligidine

Sufentanil group (Group S):Sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective laparoscopic gynecologic surgery; age 18-65 years; ASA class I-III; BMI 18-28 kg/m2; signed informed consent.

Exclusion criteria

Exclusion criteria: Patients with preoperative MMSE score =17 or inability to complete the scale assessment; history of comorbid psychiatric disorders, chronic pain, alcohol or drug abuse; significant abnormalities in severe cardiac, pulmonary, hepatic, and renal function (transaminases elevated 2-fold or more); allergy to the test medication; body weight <45Kg, BMI =28kg/m2; pregnant or lactating women; preoperative PaO2 <60 mmHg or SpO2 <92%; participation in another clinical study of the drug within the last 30 days.

Design outcomes

Primary

Measure	Time frame
Qor-15;Total amount of analgesic pumps pumped;Postoperative sedation score;	—

Secondary

Measure	Time frame
VAS score;Number of analgesic pump presses;POD;Post-hoc remedial analgesia;Post-hoc application of antiemetic drugs;Postoperative extubation time;	—

Countries

China

Contacts

Public ContactCongjie Bi

Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)

bcj0411@126.com+86 135 0425 1513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026